Email updates

Keep up to date with the latest news and content from BMC Biotechnology and BioMed Central.

Open Access Highly Accessed Review

Microfluidic chip-based technologies: emerging platforms for cancer diagnosis

Li Ying1 and Qi Wang2*

Author Affiliations

1 Department of Gastroenterology Medicine, The Second Hospital Affiliated to Dalian Medical University, Dalian, China

2 Department of Respiratory Medicine, The Second Hospital Affiliated to Dalian Medical University, Dalian, China

For all author emails, please log on.

BMC Biotechnology 2013, 13:76  doi:10.1186/1472-6750-13-76

Published: 27 September 2013

Abstract

The development of early and personalized diagnostic protocols is considered the most promising avenue to decrease mortality from cancer and improve outcome. The emerging microfluidic-based analyzing platforms hold high promises to fulfill high-throughput and high-precision screening with reduced equipment cost and low analysis time, as compared to traditional bulky counterparts in bench-top laboratories. This article overviewed the potential applications of microfluidic technologies for detection and monitoring of cancer through nucleic acid and protein biomarker analysis. The implications of the technologies in cancer cytology that can provide functional personalized diagnosis were highlighted. Finally, the future niches for using microfluidic-based systems in tumor screening were briefly discussed.

Keywords:
Microfluidics; Diagnosis; Oncology; Gene; Cancer biomarker